Commitments and Contingencies (Details) € in Millions |
1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 01, 2020 |
Jul. 05, 2019 |
Nov. 16, 2018 |
Nov. 30, 2021
USD ($)
|
Aug. 20, 2021
USD ($)
|
Mar. 24, 2021
USD ($)
|
Jan. 26, 2021 |
Mar. 24, 2019 |
Oct. 31, 2018 |
Sep. 30, 2021 |
Dec. 31, 2021
USD ($)
|
Dec. 31, 2021
EUR (€)
|
Dec. 31, 2020
USD ($)
|
Aug. 17, 2021 |
|
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||
| License fees and milestone payments, description | the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income. | the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income. | ||||||||||||
| License royalty expenses | $ 40,000 | $ 40,000 | ||||||||||||
| Master services agreement, description | the MSA will total approximately $300,000, of which shares of the Company’s common stock having a value equal to twenty percent (20%) of this total can be issued to Dr. Johnson in lieu of cash payment | The MSA has a term of five years, automatically renewed for two-year periods, unless either party gives written notice of a decision not to renew the agreement six months prior to automatic renewal. | ||||||||||||
| Service agreement, description | the MSA for a 24 week, multi-centered, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical study of the Company’s lead compound, AD04 for fees, as amended, of $3,603,351 (€3,168,895 converted to dollars at the Euro/US Dollar exchange rate of 1.1371 as of December 31, 2021) milestone payments. Through the end of 2020, 60% of the fee, a total of €1,619,626 in milestones, had been paid. | |||||||||||||
| Milestone payment | (223,104) | 303,881 | ||||||||||||
| Fees to investigators | 2,268,640 | |||||||||||||
| Accrued expenses liability | $ 441,008 | |||||||||||||
| Additional settlement expenses | $ 181,013 | |||||||||||||
| Total liability | $ 777,000 | |||||||||||||
| Operating lease remaining lease description | The Company has one operating lease which consists of office space with a remaining lease term of approximately five years. | The Company has one operating lease which consists of office space with a remaining lease term of approximately five years. | ||||||||||||
| Estimated incremental borrowing rate | 9.00% | |||||||||||||
| Future lease payments included in the measurement of lease liabilities | 5 years | |||||||||||||
| Lease commitments related party, description | the Company entered into a sublease with Purnovate, LLC, a private company in which the Company’s CEO had a 28.7% equity interest, for the lease of three offices at 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901. The lease had a term of two years, and the monthly rent was $1,400. During the year ended December 31, 2021, the rent expense associated with this lease was $1,400. On acquisition of Purnovate, the sublease was terminated and the Company assumed the obligations of Purnovate’s lease. | |||||||||||||
| Consulting agreement term | 3 years | |||||||||||||
| Consulting agreement, description | Johnson’s annual fee of $375,000 per year is paid twice per month. On execution, Dr. Johnson received a signing bonus of $250,000 and option to purchase 250,000 shares of common stock. Dr. Johnson’s participation in the Grant Incentive Plan (see below) and 2017 Equity Incentive Plan continue unaffected. | |||||||||||||
| Recognized expenses | $ 293,262 | 147,120 | ||||||||||||
| Charged against cash advanced | 219,823 | 108,056 | ||||||||||||
| Net prepaid expense asset | $ 111,767 | |||||||||||||
| Future cash | 1,200,000 | |||||||||||||
| Sixth Milestone [Member] | ||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||
| Milestone payment percentage | 60.00% | |||||||||||||
| Milestone payment | $ 318,905 | |||||||||||||
| Seventh Milestone [Member] | ||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||
| Milestone payment percentage | 100.00% | |||||||||||||
| Milestone payment | $ 317,042 | |||||||||||||
| Service Agreement 1 [Member] | ||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||
| Accrued R&D expenses | 53,065 | |||||||||||||
| Accrued R&D expense | 952,467 | |||||||||||||
| Estimated cost | 2,500,000 | € 2.2 | ||||||||||||
| Estimated future site costs | $ 3,000,000 | |||||||||||||